Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
192
resultados
Última actualización
15/06/2025 [06:53:00]
Resultados 75 a 100 de 192
Resumen de: CN120093932A
本发明属于药物载体技术领域，涉及一类可离子化脂质分子、其组合物与应用。该脂质分子包括通过可水解的酯键间接连接氨基酸结构部分和生育酚脂质结构部分，其中，可离子化基团为氨基酸结构部分的碱性基团。在优选的实施例中，间接连接氨基酸结构部分与生育酚脂质结构部分为亚烷基醚；氨基酸结构部分为赖氨酸、组氨酸、精氨酸，或及其衍生物的残基。本发明还公开了包括一种或多种可离子化脂质分子与治疗剂或预防剂制成的组合物，以及该脂质分子或组合物在制备核酸药物、小分子药物、多肽或蛋白质药物中的应用，其中，所制备的负载RNA脂质纳米粒，可在体内表达或沉默蛋白，具有稳定性好、转染效率高、毒性低、安全有效等优点。
Resumen de: CN120093913A
本发明提供一种多功能抗菌纳米粒子，所述抗菌纳米粒子为包含以下组分(A)至(C)的原料组合物的交联产物：(A)如下式(I)所示的醌式共轭有机分子：#imgabs0#(B)两亲性含醛基嵌段共聚物；和，(C)L‑精氨酸。本发明的抗菌纳米粒子基于“光热杀菌‑光动力杀菌‑气体杀菌”原理协同作用根除细菌，具有良好的抗菌、消除细菌生物膜及促进伤口恢复作用，尤其适合针对耐药菌感染如耐甲氧西林葡萄球菌(MRSA)感染的治疗。
Resumen de: AU2023329918A1
Disclosed herein are lipid nanoparticles for the delivery of active agents, including nucleic acids, as well as methods of making using thereof.
Resumen de: US2024245620A1
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Resumen de: US2025034080A1
A novel type of cationic lipid and PEGylated derivative thereof, a cationic liposome and a cationic liposome-nucleic acid pharmaceutical composition containing the cationic lipid and formulation thereof include an ionizable lipid compound of the general formula (1). This compound is slightly ionized or neutral at physiological pH but undergoes greater ionization under acidic conditions, exhibiting lower toxicity in the systemic circulation and improved endosomal escape ability. The compound's polar head contains an ionizable tertiary amine group along with a side chain containing functional groups, while the tail chains may include linking groups that are easily degraded. Cationic liposomes containing the compound have a better ability to complex with nucleic acid drugs, higher stability in serum, no apparent cytotoxicity, and high transfection efficiency.
Resumen de: CN120093671A
本发明涉及一种自驱动微型机器人双载药系统、其制备方法及应用，属于医药技术领域。自驱动微型机器人双载药系统由PLGA微针和覆盖PLGA微针上的泡腾底座构成；其中，PLGA微针的针腔里面镶嵌着自驱动蛋壳微颗粒和叠氮化外泌体的连接体，泡腾底座中包裹着血管内皮生长因子脂质颗粒。本发明提供的自驱动微型机器人双载药系统，能够巧妙地利用介质中的能量源自主移动，这一特性使其在疾病部位直接装载、运输和递送治疗药物成为可能，显著提升了治疗效果，并大幅降低了高度毒性药物的全身副作用。
Resumen de: CN120098070A
本发明属于生物医药领域，具体涉及射线响应型自组装多肽、其水凝胶和应用。本发明的射线响应型自组装多肽衍生物水凝胶具有合成方法简单、生物相容性好、易于负载药物等优点。该水凝胶能够通过射线响应触发脉冲式药物释放，时空可控地精确调控药物的释放速率，增强放疗与药物治疗的协同效果。由于其高生物安全性，可避免对人体的长期负面影响，具有非常广阔的应用前景。因此，本发明的射线响应型多肽水凝胶可广泛应用于肿瘤放疗联合治疗、术后组织修复与再生、核药递送及核医学影像引导的治疗等与放射相关的疾病治疗中，提供更加精准和有效的协同治疗方案。
Resumen de: CN120093711A
本发明公开了一种香叶木素纳米结构脂质载体，它由以下重量配比的原料制成：香叶木素5‑10%；脂质材料50‑70%；甘露糖修饰的胆固醇8‑20%；乳化剂15‑25%，属于生物医药领域。本发明通过制备纳米结构脂质载体提高了香叶木素的稳定性，延缓了药物在体内的释放速度，提高了血药浓度和生物利用度，并且还提高了药物的肺部靶向性，降低了药物的细胞毒性，在非小细胞肺癌的临床治疗中有很好的应用前景。
Resumen de: WO2025116530A1
The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition for subcutaneous administration, comprising same, and a preparation method therefor. If the preparation method of the present invention is used, nanoparticles comprising sirolimus and albumin and having excellent improved particle size distribution maintenance stability can be prepared, and the prepared nanoparticles can be prepared in a pharmaceutical composition suitable for subcutaneous injection, and thus dosage is increased and convenience of administration is improved.
Resumen de: WO2025114520A1
The present invention relates to ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety. The ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety, disclosed herein, are useful in delivering an agent to a cell or in transfecting a cell, especially for gene therapy or for gene editing.
Resumen de: WO2025116518A1
The present invention relates to a pharmaceutical composition and an oral composition, which comprise nano-graphene oxide or a variant thereof for preventing or treating oral diseases, wherein the nano-graphene oxide or the variant thereof can prevent and treat various oral diseases including gingivitis through antibacterial, anti-inflammatory and osteoclast differentiation-promoting factor reduction effects in the oral cavity, and thus the present invention can be applied to various oral care products.
Resumen de: WO2025116176A1
The present invention relates to nanoparticles which comprise: a liposome core; a chitosan coating layer on the surface thereof; and bromelain bound to at least a part of chitosan of the chitosan coating layer, thereby facilitating mucus attachment and penetration and having excellent stability.
Resumen de: WO2025113478A1
A tumor nano-vaccine and a preparation method therefor, belonging to the technical field of biopharmaceuticals. The tumor nano-vaccine comprises tumor cell lysate nanoparticles. The tumor cell lysate nanoparticles are formed by taking an acryloyl ester as a monomer, utilizing a biodegradable cross-linking agent, and synthesizing in situ a nano-thickness polymer shell on the surface of a protein or a tumor specific antigen in a tumor cell lysate by utilizing a free radical polymerization reaction. The tumor cell lysate nanoparticles can enhance the immunogenicity of a tumor antigen, thereby improving the immune response of an organism to a tumor. The tumor nano-vaccine enhances the stability of the tumor antigen, thereby ensuring the in vivo persistent circulation of the tumor antigen, and induces the organism to generate cell immunity and activate T cells, thereby achieving the effect of treating and/or preventing tumors.
Resumen de: WO2025113656A1
An ionizable cationic lipid compound having a structure represented by formula (I), which can be used to prepare lipid nanoparticles (LNP) for the delivery of a therapeutic and/or prophylactic agent. The LNP prepared using the ionizable cationic lipid compound has good stability and transfection efficiency, and can efficiently and stably deliver bioactive substances (including nucleic acids, such as mRNA) to target cells or organs, thereby eliciting a high-specificity antibody response in vivo.
Resumen de: WO2025113654A1
An ionizable cationic lipid compound having a structure as represented by formula (I), which can be used for preparing a lipid nanoparticle (LNP) for the delivery of a therapeutic agent and/or a prophylactic agent. The LNP prepared with the ionizable cationic lipid compound has a better stability and transfection efficiency, and can efficiently and stably deliver a bioactive substance (comprising a nucleic acid, e.g., mRNA) to a target cell or organ, thereby eliciting a highly specific antibody response in vivo.
Resumen de: WO2025113662A1
Provided are a lipid nanoparticle composition for delivering a nucleic acid drug, a preparation method therefor, and use thereof. The lipid nanoparticle composition comprises three lipid components: a steroid-cationic lipid compound, a neutral phospholipid, and a polyethylene glycol lipid. The composition prepared by mixing the described components has relatively good stability and transfection efficiency. The lipid nanoparticle is used for delivering nucleic acid, such as mRNA, can efficiently and stably deliver the nucleic acid drug to a target cell or organ, and can induce a relatively high specific antibody response in an experimental animal, and the antibody has a better safety profile.
Resumen de: WO2025113255A1
The present invention provides a composite molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and uses of the composite molecule, the nucleic acid, the vector, the host cell, and the pharmaceutical composition in preparation of drugs for treating cancers. The composite molecule comprises an anti-tumor antibody domain, a linker, and pro-IL-15; the anti-tumor antibody domain is linked to the pro-IL-15 by means of the linker; the anti-tumor antibody domain is a complete antibody against an immune checkpoint molecule, a tumor antigen molecule or an immune activation molecule, or a nano antibody or an antigen binding fragment thereof; the linker is a polypeptide linker or a non-peptide linker; the pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, and a linker peptide, and optionally comprising an IL-15Rβ extracellular domain; and the IL-15Rβ extracellular domain, the IL-15, and the IL-15Rα sushi domain are linked by means of the linker peptide.
Resumen de: WO2025112086A1
Disclosed are an oxidation-responsive cationic water-soluble pillararene, and a preparation method and a use. The oxidation-responsive water-soluble cationic pillararene is a cyclic small-molecule nucleic acid carrier and is obtained by carrying out quaternization reaction on 4-methyl borate and a tertiary amine modified pillararene. A delivery carrier having a high positive charge density is obtained by means of small molecule synthesis, the delivery carrier can tightly bind with a negatively-charged nucleic acid substance to form a nanocomposite, and after entering cells, in an oxidative environment, positive charges of the carrier fall off and the nucleic acid substance is released to efficiently express nucleic acid information.
Resumen de: US2025179096A1
Disclosed are an oxidation-responsive water-soluble cationic pillararene, and a preparation method and application thereof, the oxidation-responsive water-soluble cationic pillararene is a cyclic small-molecule nucleic acid vector, and is obtained by quaternization reaction of 4-methylborate and tertiary amine-modified pillararene. According to the invention, a delivery vector with a high positive charge density is obtained through small molecule synthesis, the delivery vector is capable of being tightly complexed with negatively charged nucleic acid substances to form a nano-composite, and after the nano-composite enters cells, vector positive charges fall off to release the nucleic acid substances in an oxidation environment, and nucleic acid is efficiently translated and expressed. The delivery vector has the characteristics of simplicity and convenience in synthesis, high delivery efficiency and good biological safety, and has a good application prospect.
Resumen de: US2025177423A1
Provided herein is a photoresponsive prodrug comprising an active agent conjugated to a photoresponsive group, and a nanoparticle, wherein the photoresponsive prodrug is co-assembled with a polymer to form a nanoparticle. Also provided is a method of treating a subject, comprising administering photoresponsive prodrug or the nanoparticle to the subject, and irradiating at the target site with a light source.
Resumen de: US2025177360A1
Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
Resumen de: US2025177356A1
Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
Resumen de: US2025177514A1
The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof, the variant coronavirus spike proteins having one or more modifications compared to the native coronavirus spike protein that: increase adoption by a receptor binding domain (RBD) of the variant coronavirus spike protein of an up conformation; and/or decrease adoption by a RBD of the variant coronavirus spike protein of a down conformation; and/or increase expression of the variant coronavirus spike protein compared to the native coronavirus spike protein; and/or increase adoption of a prefusion conformation; and/or decrease shedding of a S1 subunit of the variant coronavirus spike protein; and/or improve localization of the variant coronavirus spike protein to a host cell membrane. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.
Resumen de: US2025177512A1
The present specification relates to vaccines comprising an mRNA polynucleotide encoding an antigen from an infectious microorganism; and an amphipathic cell penetrating RALA peptide.
Nº publicación: US2025177503A1 05/06/2025
Solicitante:
THE REGENTS OF THE UNIV OF MICHIGAN [US]
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Resumen de: US2025177503A1
The present invention relates to compositions comprising nanoparticles associated with or without one or more tolerogenic antigens, and compositions comprising an immunomodulatory agent (e.g., interleukin-2 (IL-2) or an IL-2 variant or an IL-2/IC)), and related methods involving co-administration of such compositions for purposes of inducing amplification of regulatory T cells (Tregs) (e.g., antigen-specific regulatory Tregs). The present invention further provides methods of treating autoimmune disorders through administering to a subject a composition comprising nanoparticles associated with or without one or more tolerogenic antigens associated with the autoimmune disorder prior to administering to the subject a composition comprising an immunomodulatory agent.
BOPI
Sede Electrónica
